Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape
Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
Read More
Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma
A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.
Read More
Metastatic Urothelial Carcinoma: Intensifying Maintenance Immunotherapy
Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.
Read More
Real-World Data With Avelumab Maintenance Therapy in Metastatic Urothelial Carcinoma
Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.
Read More
Goals of Maintenance Therapy in Metastatic Urothelial Carcinoma
A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.
Read More
Metastatic Urothelial Carcinoma: Number of Frontline Chemotherapy Cycles
A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.
Read More
First-Line Treatment Options for Patients With Metastatic Urothelial Carcinoma
Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.
Read More
Novel Treatment Strategies in Muscle Invasive Bladder Cancer
A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.
Read More
Clinical Trial Data With Perioperative Therapy in MIBC: Bladder BRIDGister
Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.
Read More
Clinical Trial Data With Perioperative Therapy in MIBC: HCRN GU 16-257
Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.
Read More
Clinical Trial Data With Perioperative Therapy in MIBC: The RETAIN BLADDER Study
Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.
Read More
Muscle-Invasive Bladder Cancer: Role of Minimal Residual Disease in Adjuvant Therapy
Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.
Read More
Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer
Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.
Read More
Evolving Neoadjuvant Treatment Strategies in Muscle-Invasive Bladder Cancer
Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.
Read More
MIBC and mUC: Surgery, Systemic Therapy, and Bladder Preserving Treatments
Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.
Read More
Novel Treatment Strategies in Non-Muscle Invasive Bladder Cancer
A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.
Read More
How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma?
A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.
Read More
Overview of Practice Patterns in Urothelial Carcinoma
A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.
Read More